BioCentury | Apr 16, 2012
Financial News

Avir Green completes venture financing

Avir Green Hills Biotechnology AG , Vienna, Austria Business: Infectious, Cancer Date completed: 3/30/12 Type: Venture financing Raised: Not disclosed Note: The company raised an undisclosed amount in a convertible bond financing. WIR Staff cancer Infectious...
BioCentury | Apr 9, 2012
Clinical News

Seasonal deltaFLU: Phase I/II data

...the deltaFLU vaccine was well tolerated and induced immune responses against all 3 vaccine strains. Avir Green Hills Biotechnology AG...
BioCentury | Jan 18, 2010
Clinical News

Seasonal H1N1 deltaFLU: Phase I data

...from a placebo-controlled Phase I trial in 48 healthy volunteers showed that escalating doses of Avir Green...
...against other strains of influenza virus. Data were published in the Journal of Infectious Diseases. Avir Green Hills Biotechnology AG...
BioCentury | Jan 18, 2010
Clinical News

Seasonal H1N1 deltaFLU: Phase II started

...double-blind, Austrian Phase II trial to evaluate intranasal Seasonal H1N1 deltaFLU in 48 healthy volunteers. Avir Green Hills Biotechnology AG...
BioCentury | Jun 29, 2009
Clinical News

Avir Green preclinical data

...H5N1 influenza virus strains. deltaFLU Envax is an intranasal influenza vaccine lacking the NS1 gene. Avir Green Hills Biotechnology AG...
BioCentury | May 4, 2009
Product Development

Vaccine Manufacturing Technologies

...Vaccine Manufacturing Technologies Company Vaccine manufacturing technology Avir Green Hills Biotechnology AG deltaFLU technology uses tissue cultures to produce vaccine...
BioCentury | Jul 21, 2008
Clinical News

Fluvacc: Phase I started

...Avir began a double-blind, Austrian Phase I trial in healthy volunteers. Avir Green Hills Biotechnology AG , Vienna, Austria Product...
BioCentury | May 21, 2007
Clinical News

Fluvacc: Phase I started

...Avir began an Austrian Phase I trial of intranasal Fluvacc in 24 healthy male volunteers. Avir Green Hills Biotechnology AG...
BioCentury | Apr 23, 2007
Clinical News

Envax: Phase I start

...Avir began a Phase I trial of intranasal Envax in 24 healthy male volunteers. Avir Green Hills Biotechnology AG...
Items per page:
1 - 9 of 9
BioCentury | Apr 16, 2012
Financial News

Avir Green completes venture financing

Avir Green Hills Biotechnology AG , Vienna, Austria Business: Infectious, Cancer Date completed: 3/30/12 Type: Venture financing Raised: Not disclosed Note: The company raised an undisclosed amount in a convertible bond financing. WIR Staff cancer Infectious...
BioCentury | Apr 9, 2012
Clinical News

Seasonal deltaFLU: Phase I/II data

...the deltaFLU vaccine was well tolerated and induced immune responses against all 3 vaccine strains. Avir Green Hills Biotechnology AG...
BioCentury | Jan 18, 2010
Clinical News

Seasonal H1N1 deltaFLU: Phase I data

...from a placebo-controlled Phase I trial in 48 healthy volunteers showed that escalating doses of Avir Green...
...against other strains of influenza virus. Data were published in the Journal of Infectious Diseases. Avir Green Hills Biotechnology AG...
BioCentury | Jan 18, 2010
Clinical News

Seasonal H1N1 deltaFLU: Phase II started

...double-blind, Austrian Phase II trial to evaluate intranasal Seasonal H1N1 deltaFLU in 48 healthy volunteers. Avir Green Hills Biotechnology AG...
BioCentury | Jun 29, 2009
Clinical News

Avir Green preclinical data

...H5N1 influenza virus strains. deltaFLU Envax is an intranasal influenza vaccine lacking the NS1 gene. Avir Green Hills Biotechnology AG...
BioCentury | May 4, 2009
Product Development

Vaccine Manufacturing Technologies

...Vaccine Manufacturing Technologies Company Vaccine manufacturing technology Avir Green Hills Biotechnology AG deltaFLU technology uses tissue cultures to produce vaccine...
BioCentury | Jul 21, 2008
Clinical News

Fluvacc: Phase I started

...Avir began a double-blind, Austrian Phase I trial in healthy volunteers. Avir Green Hills Biotechnology AG , Vienna, Austria Product...
BioCentury | May 21, 2007
Clinical News

Fluvacc: Phase I started

...Avir began an Austrian Phase I trial of intranasal Fluvacc in 24 healthy male volunteers. Avir Green Hills Biotechnology AG...
BioCentury | Apr 23, 2007
Clinical News

Envax: Phase I start

...Avir began a Phase I trial of intranasal Envax in 24 healthy male volunteers. Avir Green Hills Biotechnology AG...
Items per page:
1 - 9 of 9